Lantern Pharma Inc. Q3 2025 Earnings Recap

LTRN Q3 2025 November 13, 2025

Get alerts when LTRN reports next quarter

Lantern Pharma achieved significant clinical and regulatory milestones in Q3 2025, particularly with the successful Phase Ia trial of LP-184, which demonstrated a 48% clinical benefit rate in evaluable cancer patients.

Earnings Per Share Beat

$-0.39 vs $-0.46 est.

+15.2% surprise

Market Reaction

1-Day -0.57%

5-Day -7.76%

30-Day +10.63%

See LTRN alongside your other holdings

Add to your portfolio — free

Key Takeaways

LP-184's Phase Ia trial met all primary endpoints, with notable tumor reductions in patients with specific DNA damage repair mutations.
Starlight Therapeutics received favorable guidance from the FDA for its planned pediatric CNS cancer trial, combining LP-184 with spironolactone.
Preliminary Phase II data from the LP-300 HARMONIC trial was presented, with a comprehensive update expected in December.
Lantern is advancing LP-184 into targeted Phase Ib/II trials across four significant oncology indications, with a potential market exceeding $7 billion.
The RADR AI platform demonstrated commercial readiness, with viable modules for licensing to biopharma partners.

This summary was generated by AI from the official earnings call transcript and is provided for informational purposes only. It does not constitute financial advice. For the complete transcript and financial data, visit LTRN on AllInvestView.